Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells

Journal of Clinical Investigation

Volumn 95, Issue 5, 1995, Pages 2096-2103

  Nip, John ^a   Rabbani, Shafaat A ^b   Shibata, Henry R ^a   Brodt, Pnina ^a  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

integrin; melanoma; metastasis; urokinase plasminogen activator receptor; vitronectin receptor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL RECEPTOR; COMPLEMENTARY DNA; CYCLOPHILIN; FIBRONECTIN; INTEGRIN; LAMININ; MESSENGER RNA; MONOCLONAL ANTIBODY; POLYADENYLATED RNA; POLYCLONAL ANTIBODY; UROKINASE; VITRONECTIN;

ANIMAL CELL; ARTICLE; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0028962771     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117897     Document Type: Article

References (47)

1. Rigel, D. S. 1992. Epidemiology and prognostic factors in malignant melanoma. Ann. Plas. Surg. 28:7-8.
2. Glass, A. G., and R. N. Hoover. 1989. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA (J. Am. Med. Assoc.) 262:2097-2100.
3. Beahrs, O. H., and M. H. Myers. 1981. Purposes and principles of staging. In Manual for Staging of Cancer. O. H. Beahrs and M. H. Myers, editors. J. B. Lippincott Co., Philadelphia. 3-5.
4. Liotta, L., C. N. Rao, and U. M. Wewer. 1986. Biochemical interaction of tumor cells with the basement membrane. Ann. Rev. Biochem. 55:1037-1057.
5. Hynes, R. O. 1992. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 69:11-25.
6. 3 subunit with tumor progression. Cancer Res. 50:6757-6764.
7. 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. USA. 89:1557-1561.
8. Felding-Habermann, B., B. M. Mueller, C. A. Romerdahl, and D. A. Cheresh. 1992. Involvement of integrin αV gene expression in human melanoma tumorigenecity. J. Clin. Invest. 89:2018-2022.
9. 3 to adhere to lymph node vitronectin. J. Clin. Invest. 90:1406-1413.
10. Achbarou, A., S. Kaiser, G. Tremblay, L.-G. Ste-Marie, P. Brodt, D. Goltzman, and S. A. Rabbani. 1994. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:2372-2377.
11. Meissauer, A., M. D. Kramer, V. Schirrmacher, and G. Brunner. 1992. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp. Cell Res. 199:179-190.
12. Hearing, V. J., L. W. Law, A. Corti, E. Appella, and F. Blasi. 1987. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 48:1270-1278.
13. Blasi, F. 1993. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 15:105-111.
14. Cheresh, P. A., and R. C. Spiro. 1987. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma attachment to vitronectin, fibrinogen and vonWillebrand factor. J. Biol. Chem. 262:17703-17711.
15. 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113:919-929.
16. Weitzman, J. B., R. Pasqualini, Y. Takada, and M. E. Hemler. 1993. The function and distinctive regulation of the integrin VLA-3 in cell adhesion, spreading, and homotypic cell aggregation. J. Biol. Chem. 268:8651-8657.
17. Rabbani, S. A., A. P. Mazar, S. M. Bernier, M. Haq, I. Bolivar, J. Henkin, and D. Goltzman. 1992. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J. Biol. Chem. 267:14151-14156.
18. Suzuki, S., W. S. Argraves, R. Pytela, H. Arai, T. Krusius, M. D. Pierschbacher, and E. Ruoslahti. 1986. cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors. Proc. Natl. Acad. Sci. USA. 83:8614-8618.
19. Roldan, A. L., M. V. Cubellis, M. T. Masucci, N. Behrendt, L. R. Lund, K. Dano, E. Appella, and F. Blasi. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO (Eur. Mol. Biol. Org.) J. 9:467-474.
20. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.
21. Johnstone, A., and R. Thorpe. 1987. Immunochemistry in Practice. 2nd ed. Blackwell Scientific Publications Ltd., London. 122-124.
22. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
23. Feinberg, V., and B. Vogelstein. 1984. A technique for labelling DNA restriction endonuclease fragments to high specificity. Anal. Biochem. 132:6-13.
24. Ullrich, A., C. H. Berman, T. J. Dull, A. Gray, and J. M. Lee. 1984. Isolation of the human insulin-like growth factor I gene using a single synthetic DNA probe. EMBO (Eur. Mol. Biol. Org.) J. 3:361-364.
25. Danielson, P. E., S. Rorss-Petter, M. A. Bow, L. Calaretta, J. Douglass, R. J. Milner, and J. C. Sutcliffe. 1988. A cDNA clone of the rat mRNA encoding cyclophilin. DNA (NY). 7:261-267.
26. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-detected enzymatic amplification of DNA with thermostable DNA polymerase. Science (Wash. DC). 239:487-491.
27. deVries, T. J., P. H. Quax, M. Denijn, K. N. Verrijp, J. H. Verheijen, H. W. Verspaget, U. H. Weidle, D. J. Ruiter, and G. N. P. van Muijen. 1994. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol. 144:70-81.
28. Waltz, D. A., and H. A. Chapman. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269:14746-14750.
29. Grondahl-Hansen, J., E. Ralfkiaer, L. T. Kirkeby, P. Kristensen, L. R. Lund, and K. Dano. 1991. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am. J. Pathol. 138:111-117.
30. Pyke, C., P. Kristensen, E. Ralfkiaer, J. Grondahl-Hansen, J. Eriksen, F. Blasi, and K. Dano. 1991. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 138:1059-1067.
31. Saksela, O., T. Hovi, and A. Vaheri. 1985. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J. Cell. Physiol. 122:125-132.
32. Flaumenhaft, R., M. Abe, P. Mignatti, and D. B. Rifkin. 1992. Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity. J. Cell Biol. 118:901-909.
33. Lund, L. R., J. Rømer, E. Rønne, V. Ellis, F. Blasi, and K. Danø. 1991. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor β1 in human A549 lung carcinoma cells. EMBO (Eur. Mol. Biol. Org.) J. 10:3399-3407.
34. Mattel, S., M. P. Colombo, C. Melani, A. Silvani, G. Parmiani, and M. Herlyn. 1994. Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int. J. Cancer. 56:853-857.
35. Rodeck, U., A. Bossler, U. Graeven, F. E. Fox, P. C. Nowell, C. Knabbe, and C. Kari. 1994. Transforming growth factor β production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:575-581.
36. 5 monoclonal antibodies. J. Cell Sci. 105:101-111.
37. Sanchez-Mateos, P., A. G. Arroyo, M. A. Balboa, and F. Sanchez-Madrid. 1993. Post-receptor occupancy events in leukocytes during beta 1 integrin-ligand interactions. Eur. J. Immunol. 23:2642-2648.
38. Pelletier, A. J., S. C. Bodary, and A. D. Levinson. 1992. Signal transduction by the platelet integrin alpha Hb beta 3: induction of calcium oscillations required for protein-tyrosine phosphorylation and ligand-induced spreading of stably transfected cells. Mol. Biol. Cell. 3:989-998.
39. Yurochko, A. D., D. Y. Liu, D. Eierman, and S. Haskill. 1992. Integrins as a primary signal transduction molecule regulating monocyte immediate-early gene induction. Proc. Natl. Acad. Sci. USA. 89:9034-9038.
40. Leavesley, D. I., M. A. Schwartz, M. Rosenfeld, and D. A. Cheresh. 1993. Integrin β 1-and β 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J. Cell Biol. 121:163-170.
41. 3 for angiogenesis. Science (Wash. DC). 264:569-571.
42. Bartfeld, N. S., E. B. Pasquale, J. E. Geltosky, and L. R. Languino. 1993. The alpha v beta 3 integrin associates with a 190-kDa protein that is phosphorylated on tyrosine in response to platelet-derived growth factor. J. Biol. Chem. 268:17270-17276.
43. Stahl, A., and B. M. Mueller. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:3066-3071.
44. Pepper, M. S., A.-P. Sappino, R. Stocklin, R. Montesano, L. Orci, and J.-D. Vassalli. 1993. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122:673-684.
45. Odekon, L. E., F. Blasi, and D. B. Rifkin. 1994. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF-beta. J. Cell. Physiol. 158:398-407.
46. Kerbel, R. S. 1992. Expression of multi-cytokine resistance and multigrowth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am. J. Pathol. 141:519-524.
47. Nip, J., and P. Brodt. 1994. Melanoma cell adhesion through integrin potentiates a proliferative response to a lymph node stromal cell-derived growth factor. Proc. Am. Assoc. Cancer Res. 35:334a. (Abstr.)